Vanguard Group
SRRA

Vanguard Group’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Vanguard Group’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-645,672
Closed -$35.5M – 4660
2022
Q2 		$35.5M Buy
645,672
+272,823
+73% +$14.3M ﹤0.01% 2355
2022
Q1 		$11.9M Buy
372,849
+97,391
+35% +$2.79M ﹤0.01% 3056
2021
Q4 		$5.99M Buy
275,458
+46,200
+20% +$1.02M ﹤0.01% 3509
2021
Q3 		$5.03M Buy
+229,258
New +$4.59M ﹤0.01% 3661

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Vanguard Group's SRRA Position: Q3 2022 in Review

Vanguard Group sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 645,672 shares — an estimated $35.5M sold.

Vanguard Group first reported a position in SRRA in Q3 2021 and held it in 4 quarters. The position peaked at $35.5M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Vanguard Group reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Vanguard Group sold 645,672 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $35.5M.
  • Vanguard Group first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Vanguard Group's Sierra Oncology, Inc. Common Stock position peaked at $35.5M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.